Stifel Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $15
Stifel Nicolaus Keeps Their Buy Rating on Black Diamond Therapeutics (BDTX)
Black Diamond Theraptcs Price Target Raised to $12.00/Share From $11.00 by HC Wainwright & Co.
Black Diamond Theraptcs Is Maintained at Buy by Stifel
Black Diamond Therapeutic Analyst Ratings
Wedbush Adjusts Black Diamond Therapeutics Price Target to $11 From $16, Maintains Outperform Rating
Analysts Offer Insights on Healthcare Companies: Ventyx Biosciences (VTYX), Black Diamond Therapeutics (BDTX) and Passage Bio (PASG)
TD Cowen Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating
Stifel Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Cuts Target Price to $16
Black Diamond Therapeutic Analyst Ratings
TD Cowen Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating
H.C. Wainwright Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $11
Strong Buy Rating for Black Diamond Therapeutics Driven by Financial Stability and Promising Clinical Developments
H.C. Wainwright Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $11
A Quick Look at Today's Ratings for Black Diamond Therapeutics(BDTX.US), With a Forecast Between $11 to $16
Analysts Are Bullish on These Healthcare Stocks: Black Diamond Therapeutics (BDTX), MiNK Therapeutics (INKT)
Black Diamond Therapeutic Analyst Ratings
TD Cowen Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating
Wedbush Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $16
Piper Sandler Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $15